Artrya secures significant funding

Artrya (ASX:AYA), a healthcare company focused on AI diagnostics for coronary heart disease, has successfully raised A$5 million via a placement to sophisticated and professional investors. The placement was priced at A$0.42 per share, representing a 16% discount to the last closing price. The funds will be used for product development, R&D, regulatory work, and more, as the company awaits FDA clearance for its Salix® Coronary Anatomy product.

Artrya's strategic funding move

Artrya has successfully raised A$5 million through a placement, marking a significant milestone in its funding efforts. The placement was oversubscribed, demonstrating strong investor interest. The introduction of Healthliant Ventures, linked to a major US hospital system, may lead to strategic partnerships. The funds raised will bolster Artrya's product and clinical development, particularly as the company seeks FDA clearance for its Salix® Coronary Anatomy product. The placement reflects Artrya's commitment to advancing AI healthcare solutions, with strategic pricing to attract investors despite market conditions. The company's ambitions include expanding into the US market and enhancing its AI platform for coronary artery disease detection.

Executive insights on successful placement

We are grateful for the support of both new and existing investors. The placement will allow us to continue our strategic initiatives and prepare for future growth opportunities.